Pharmasum Therapeutics is a private Norwegian pharmaceutical company dedicated to discovering and developing innovative drugs to treat neurological and autoimmune/metabolic diseases with significant unmet medical needs. Their flagship product, PST-674, is a potent DYRK1A protein kinase designed to address the clinical indication of dementia, where current treatment options are limited. Pharmasum envisions that the results from their DYRK1A development program will be utilized in the treatment of Alzheimer's disease, dementia in Parkinson's Disease, Dementia with Lewy Bodies, and dementia in Down syndrome.

Located in Oslo Science Park, Norway, Pharmasum boasts an international team with extensive research and development expertise spanning Norway, the UK, and the US. The core management team, led by Co-founder and CEO Anders Fugelli, brings over 20 years of experience in academia and industrial R&D, with a strong focus on brain diseases. Complemented by a capable board of directors, including experts in clinical development, synthetic organic chemistry, and neurology, Pharmasum demonstrates a commitment to excellence in their field.

With their dedication to groundbreaking research and development, Pharmasum Therapeutics is poised to make significant contributions to the treatment options for neurological and autoimmune/metabolic diseases, improving the lives of patients worldwide